Skip to main content
Assets
Humacyte logo
HUMA.NASDAQ
Humacyte
Health Care · Biotechnology

Biotechnology company developing bioengineered human tissue products for vascular trauma, dialysis access, and regenerative medicine.

HQ: United StatesListed: United States

Historical AI Forecasts

Audit every published iPulse AI forecast batch and immutable historical research document for Humacyte.

Historical AI ConsensusHistorical AI Forecasts

Humacyte Inc (HUMA.NASDAQ) AI FORECASTS & ADVISOR ANALYSIS

Read and compare the 12 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 5 July 2026Deep analysis 5 July 2026

PublisherRusslan Ramdowar
25 min readAudit All Past Forecasts
Ray Dalio AI advisor icon

Ray Dalio AI

The Strategist FrameworkAI Researcher

Model rating

Buy

5-Year Return Est.

+647.4%

HUMA.NASDAQ does not currently pay dividends

1. Investment Thesis — Base Case

The '' path reflects a volatile but massive upward repricing as Humacyte transitions from a distressed clinical-stage cash burner to a multi-indication commercial medtech. The current $0.71 price and ~$140M represent , driven by the Warsh Fed's liquidity withdrawal and the June 2026 . However, this was a necessary cyclical bridge to a structural inflection point.

  • The V012 Phase 3 superiority data in hemodialysis unlocks a chronic, scheduled surgical market exponentially larger than unpredictable trauma.
  • The 25% workforce reduction in May 2026, combined with the recent capital raise, secures the runway past the mid-2027 FDA regulatory catalyst.
  • Domestic, commercial-scale biomanufacturing isolates the company from geopolitical shocks and disruptions.
  • As production volume scales with the dialysis launch, currently negative will rapidly inflect due to the absorption of fixed manufacturing overhead.

At a ~$140M valuation, the market is assigning zero to a platform with an approved product, superiority data in a massive second indication, and paid-for sovereign manufacturing. The implied risk/reward is heavily asymmetric, competing favorably against broad market alternatives despite the elevated path volatility.

Historical prices and published forecast

Historical prices and published forecastObserved prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.-0.843.347.5211.7115.89Jul 2021Dec 2023Jul 2026Dec 2028Jul 2031Forecast starts
  • Observed price
  • Published advisor forecast
Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.
View chart values
Historical prices and published forecast — published chart values
SeriesDateValue (USD)
Observed price2021-07-0110.24
Observed price2021-07-1310.24
Observed price2021-07-179.98
Observed price2021-07-299.96
Observed price2021-08-1410.04
Observed price2021-08-189.99
Observed price2021-09-0713.96
Observed price2021-09-1114.49
Observed price2021-10-0111.03
Observed price2021-10-0910.80
Observed price2021-10-259.82
Observed price2021-10-299.10
Observed price2021-11-1811.49
Observed price2021-11-2610.98
Observed price2021-12-1210.11
Observed price2021-12-168.71
Observed price2022-01-056.74
Observed price2022-01-096.04
Observed price2022-01-294.89
Observed price2022-02-025.03
Observed price2022-02-105.70
Observed price2022-03-145.46
Observed price2022-03-186.39
Observed price2022-03-266.42
Observed price2022-03-307.27
Observed price2022-04-197.40
Observed price2022-05-057.13
Observed price2022-05-095.70
Observed price2022-05-214.72
Observed price2022-06-026.25
Observed price2022-06-223.49
Observed price2022-06-303.21
Observed price2022-07-083.56
Observed price2022-07-203.52
Observed price2022-08-013.33
Observed price2022-08-174.80
Observed price2022-08-293.94
Observed price2022-09-104.50
Observed price2022-09-263.42
Observed price2022-10-043.38
Observed price2022-10-083.15
Observed price2022-11-013.62
Observed price2022-11-093.14
Observed price2022-11-172.90
Observed price2022-11-213.20
Observed price2022-12-113.06
Observed price2022-12-272.06
Observed price2023-01-042.14
Observed price2023-01-242.58
Observed price2023-01-282.77
Observed price2023-02-053.16
Observed price2023-03-053.21
Observed price2023-03-132.66
Observed price2023-03-212.90
Observed price2023-04-063.22
Observed price2023-04-143.25
Observed price2023-04-223.34
Observed price2023-05-084.97
Observed price2023-05-163.89
Observed price2023-06-094.29
Observed price2023-06-173.14
Observed price2023-06-293.02
Observed price2023-07-072.84
Observed price2023-07-272.77
Observed price2023-07-313.28
Observed price2023-08-083.10
Observed price2023-08-164.19
Observed price2023-09-014.04
Observed price2023-09-212.93
Observed price2023-09-292.93
Observed price2023-10-152.59
Observed price2023-10-192.34
Observed price2023-10-272.01
Observed price2023-11-122.28
Observed price2023-12-022.64
Observed price2023-12-062.64
Observed price2023-12-143.12
Observed price2023-12-302.85
Observed price2024-01-152.59
Observed price2024-01-232.91
Observed price2024-02-123.87
Observed price2024-02-204.84
Observed price2024-03-073.27
Observed price2024-03-193.49
Observed price2024-03-313.03
Observed price2024-04-122.88
Observed price2024-04-243.82
Observed price2024-04-284.06
Observed price2024-05-186.57
Observed price2024-05-309.10
Observed price2024-06-116.99
Observed price2024-06-156.76
Observed price2024-06-274.70
Observed price2024-07-095.86
Observed price2024-07-178.17
Observed price2024-08-068.30
Observed price2024-08-146.01
Observed price2024-08-267.05
Observed price2024-09-075.31
Observed price2024-09-235.23
Observed price2024-09-275.58
Observed price2024-10-135.69
Observed price2024-10-174.86
Observed price2024-11-105.61
Observed price2024-11-264.43
Observed price2024-12-124.08
Observed price2024-12-204.64
Observed price2024-12-285.36
Observed price2025-01-134.39
Observed price2025-01-254.58
Observed price2025-02-064.27
Observed price2025-02-104.13
Observed price2025-03-023.17
Observed price2025-03-223.32
Observed price2025-03-262.00
Observed price2025-03-301.79
Observed price2025-04-071.26
Observed price2025-05-091.19
Observed price2025-05-131.73
Observed price2025-05-172.24
Observed price2025-05-292.77
Observed price2025-06-102.67
Observed price2025-06-302.09
Observed price2025-07-042.25
Observed price2025-07-242.67
Observed price2025-07-282.47
Observed price2025-08-131.78
Observed price2025-08-291.55
Observed price2025-09-061.42
Observed price2025-09-141.51
Observed price2025-10-042.23
Observed price2025-10-081.69
Observed price2025-10-201.81
Observed price2025-11-011.64
Observed price2025-11-171.13
Observed price2025-11-291.33
Observed price2025-12-151.18
Observed price2025-12-310.96
Observed price2026-01-081.17
Observed price2026-01-121.13
Observed price2026-01-281.00
Observed price2026-02-050.89
Observed price2026-02-091.22
Observed price2026-03-091.20
Observed price2026-03-210.81
Observed price2026-03-250.82
Observed price2026-03-290.61
Observed price2026-04-180.70
Observed price2026-05-081.06
Observed price2026-05-120.91
Observed price2026-06-011.45
Observed price2026-06-091.39
Observed price2026-06-250.62
Observed price2026-06-290.80
Observed price2026-07-190.66
Observed price2026-07-230.64
Observed price2026-08-080.73
Observed price2026-08-200.68
Observed price2026-09-010.57
Observed price2026-09-150.55
Observed price2026-09-180.59
Published advisor forecast2026-07-020.71
Published advisor forecast2026-10-020.82
Published advisor forecast2027-01-020.96
Published advisor forecast2027-04-021.14
Published advisor forecast2027-07-021.57
Published advisor forecast2027-10-021.79
Published advisor forecast2028-01-022.07
Published advisor forecast2028-04-022.43
Published advisor forecast2028-07-022.79
Published advisor forecast2028-10-023.21
Published advisor forecast2029-01-023.56
Published advisor forecast2029-04-023.92
Published advisor forecast2029-07-024.19
Published advisor forecast2029-10-024.40
Published advisor forecast2030-01-024.62
Published advisor forecast2030-04-024.85
Published advisor forecast2030-07-025.00
Published advisor forecast2030-10-025.05
Published advisor forecast2031-01-025.10
Published advisor forecast2031-04-025.15
Published advisor forecast2031-07-025.31

2. Scenarios & Signals

Bull case

What happens if the hemodialysis launch executes flawlessly and strategic acquirers recognize the sovereign manufacturing premium? The FDA grants Priority Review for the hemodialysis sBLA, moving approval to early 2027. Fresenius Medical Care or a similar giant executes a strategic buyout or massive global distribution partnership. Unabsorbed overhead vanishes as the Durham facility hits scale, driving to medtech industry standards (70%+).

  • Priority review pulls forward revenue inflection.
  • instantly realizes fair platform value.
  • transforms into .
  • Stock re-rates from distressed micro-cap to mid-cap growth.

Bear case

What happens if the Warsh rate regime chokes liquidity before the dialysis inflection? The FDA issues a Complete Response Letter (CRL) for the dialysis sBLA, requiring another 1-2 years of clinical data. The trauma commercial ramp flatlines as hospitals resist changing standard operating procedures in emergency settings. Unabsorbed manufacturing costs bleed the dry.

  • CRL pushes revenue horizon beyond current cash runway.
  • Warsh Fed blocks access to secondary equity markets.
  • Toxic spirals destroy common equity value.
  • Asset liquidation forces a near-total loss of capital.

Current crowd narrative

The crowd and media view Humacyte as a broken, cash-burning micro-cap that failed to execute its initial commercial launch. Anchored heavily to the sluggish Q1 2026 Symvess trauma sales ($0.5M) and the highly dilutive June 2026 stock offering, consensus treats the company as a terminal liquidity victim. The dominant narrative dismisses the underlying bioengineering science, assuming that high overhead costs and the unforgiving Warsh-led will force the company into bankruptcy or endless before profitability is ever reached.

Alpha-gap assessment

The market systematically misprices the distinction between an acute, behavioral-friction trauma market and a scheduled, chronic-care hemodialysis market. The crowd assumes the slow trauma ramp reflects a defective product, blinding them to the V012 Phase 3 superiority data in dialysis. Furthermore, the market assigns zero to Humacyte's commercial-scale, domestic U.S. biomanufacturing facility—a massive, paid-for strategic moat in a deglobalizing, BIOSECURE-compliant world. The is that the recent was a necessary cyclical bridge to a structural inflection point; Humacyte is not a , it is a de-risked commercial platform wearing a .

Convergence catalyst

The submission and formal FDA acceptance of the supplemental BLA for hemodialysis access in the second half of 2026 will serve as the initial catalyst. The ultimate convergence event will be the PDUFA approval mid-2027. Confirmation will emerge when Q-over-Q forward revenue guidance shifts from incremental trauma sales to exponential dialysis volume.

Complete advisor preview locked

Unlock this report and every AI Advisor

Sign in to check your access, or upgrade to the Base plan to read this report and open every advisor.

Sign in to check accessView Base planReturn to latest AI Consensus